CellProthera Raises 8.3 Million Euros
CellProthera, a biotech company which offers the most advanced cell therapy for regeneration of the damaged heart muscle after myocardial infarction, announces it has raised €8,300,000 from private investors in 2016. These funds, supplements the 20 million€ raised during the previous rounds, and will enable CellProthera to pursue its scientific development, complete its Phase I/IIb clinical trial in Europe and prepare its Phase III in Europe and North America.
Carried out in three phases, 100% of the capital increase comes from
family offices, some of them with a history of supporting CellProthera
in previous rounds.
New stakeholders, specializing in innovation and ground-breaking technology, particularly in the medical sector, have expressed real enthusiasm for CellProthera, its progress and potential .
The funds raised will be used for three main programs:
1. Completion of the current phase I/IIb clinical trials. The company is also preparing the phase III trial, which involves setting up new cell therapy centers in Europe, the United States and Canada.
2. Development of an industrial automate. This device is at the core of the treatment offered by CellProthera; from a simple blood test, it generates, on an industrial scale and by cellular multiplication, a graft of CD34 + stem cells "ProtheraCytes®" which is re-injected into the patient.
3. CellProthera aims also to establish a foothold in Asia and will start a clinical trial in Singapore in 2017.
"With this new round, our investors have demonstrated their dedication and commitment to our project. The one million patients waiting for a therapy in Europe, the United States and Japan alone are grateful to them. "
|Philippe HENON||Jean-Claude JELSCH||Matthieu de KALBERMATTEN|
|Chairman & CSO||Chairman of the Supervisory Board||CEO|
Additional information and visuals are available on request from the press department
The original source-language text of this announcement is the official, authoritative version. Translations are provided as an accommodation only, and should be cross-referenced with the source-language text, which is the only version of the text intended to have legal effect.
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Skriv dig op her og modtag pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Business Wire
CA-NEXON-AMERICA-INC18.10.2018 22:45 | pressemeddelelse
MapleStory 2 Hits 1 Million Account Downloads
NY-BCW18.10.2018 19:19 | pressemeddelelse
Kristen Lisanti Joins BCW as Chief Culture Officer
AZ-LIMELIGHT-NETWORKS18.10.2018 17:02 | pressemeddelelse
Limelight Networks and Ericsson to Accelerate Content Delivery and Edge Cloud Adoption
KAYMERA-TECHNOLOGIES18.10.2018 15:58 | pressemeddelelse
World Leader in High-End Mobile Security, Kaymera Technologies, to Expand Adaptive Mobile Threat Defense Footprint
PIRAEUS-BANK18.10.2018 15:20 | pressemeddelelse
Piraeus Bank Signs Financing Agreement of €40 million with Thomas Cook Hotel Investments
CA-STARLEAF18.10.2018 15:02 | pressemeddelelse
StarLeaf Reinforces Its Global Expansion With New Office in Norway
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum